Navigation Links
Senokot(R) Tablets Undergo a Natural Makeover
Date:8/6/2009

STAMFORD, Conn., Aug. 6 /PRNewswire/ -- The Purdue Products L.P. line of laxatives unveiled its newest addition on June 28, at the National Association of Chain Drug Stores (NACDS) 2009 Marketplace Conference, in Boston. Newly reformulated Senokot(R) Tablets are not chemically processed, and the primary ingredient is the deseeded pod of the senna plant.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090806/NY57748 )

"We've always been proud of the fact that Senokot(R) Tablets are such a trusted laxative brand," says Charlene Bailey, Director, Product Management, Purdue Products L.P. "But we're really excited to give consumers something new - especially at a time when interest is so high in natural products." The new Senokot(R) Tablets will be available in pharmacies (drug, food and mass merchandisers) nationwide in October 2009.

Purdue will support the introduction with a comprehensive media plan that includes national television advertising, retail account programs, coupons, and rebates. In addition, the contemporary design for the brand will not only stand out on-shelf, but will also reinforce Senokot(R) and Senokot-S(R) Tablets as a natural choice for today's health-minded consumers.

With more than four million Americans reporting that they suffer from frequent constipation(1), this common digestive health complaint can be attributed to many causes. Stress, poor diet and lack of exercise can all take a toll on the body. The new, reformulated Senokot(R) and Senokot-S(R) Tablets provide an effective option that pharmacists and other healthcare professionals can feel good about recommending to consumers to treat occasional constipation associated with diet or lifestyle.

The new Senokot(R) and Senokot-S(R) Tablets will be hitting the shelves in the fall, joining the other Purdue Laxative brands, including Colace (R) Capsules and Peri-Colace(R) Tablets and rounding out the company's comprehensive offerings for relief for occasional constipation.

The Purdue Products L.P. Line of Laxatives

Senokot(R) Tablets and Colace(R) Capsules have been recommended by doctors and pharmacists for more than 50 years for effective, gentle and safe relief from occasional constipation. Colace(R) Capsules, the #1 recommended stool softener brand by doctors and pharmacists, relieves occasional constipation that may be associated with certain medical conditions. Senokot (R)Tablets provide gentle, yet effective relief for occasional constipation associated with diet or lifestyle. The Purdue laxative portfolio includes: Colace(R) Capsules, Peri-Colace(R) Tablets, Senokot(R) Tablets, Senokot-S(R) Tablets and SenokotXTRA(R) Tablets. The Purdue laxative portfolio is dedicated to providing consumers with specific solutions to the various types of occasional constipation that can occur as a part of everyday life.

(1) National Institute of Diabetes and Digestive and Kidney Diseases. (2007). National Digestive Diseases Information Clearing House: Constipation. Retrieved January 26, 2009, from http://digestive.niddk.nih.gov/ddiseases/pubs/constipation/Constipation.pdf

    Press Contact:
    Vicky Toporovsky
    Pollock Communications
    646.277.8719
    vtoporovsky@pollock-pr.com


'/>"/>
SOURCE Purdue Products L.P.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
2. Actavis Launches Carvedilol Tablets in the U.S.
3. Mylan Announces Final FDA Approval for Carvedilol Tablets
4. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
5. Actavis Launches Amlodipine Tablets in the U.S.
6. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
7. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
8. KV Pharmaceutical Announces FDA Approval for Morphine ER 100 mg and 200 mg Tablets
9. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
10. Ranbaxy Receives Tentative Approval For Valsartan Tablets
11. Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... City, NJ (PRWEB) , ... March 28, 2017 ... ... American Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a ... and their team of professional staff discussed strategies for preventing outbreaks among camp ...
(Date:3/28/2017)... ... , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in ... hair loss. Although hair transplant procedures can be seen as more of a man’s ... be two reasons a woman may see her hair thinning. , “We are used ...
(Date:3/28/2017)... ... 28, 2017 , ... Thank you to all who attended Capio Partners Winter ... event was exclusive to providers and offered an opportunity to collaborate and network with ... Manchester Grand Hyatt where attendees gathered for a lively discussion on trends and issues ...
(Date:3/28/2017)... ... ... Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A Prophets Bones” ... and teachers had asked of him that he had neglected to do, but this was ... Creator. There were some who would have felt themselves to be special and better than ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... 2017  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical ... diseases in children, today reported financial results for ... 31, 2016 and provided an update on its ... make progress during the fourth quarter of 2016 ... primate safety study, and with our lead development ...
(Date:3/24/2017)... , Mar 24, 2017 Research ... Therapy Manufacturing Market, 2017-2027" report to their offering. ... The Cell ... the rapidly growing market of cell therapy manufacturing and focuses ... manufacturing facilities. These therapies are anticipated to emerge as viable ...
Breaking Medicine Technology: